1,276 results on '"Blay, J. Y."'
Search Results
2. Policy strategies for capacity building and scale up of the workforce for comprehensive cancer care: a systematic review
3. Impact of artificial intelligence in transforming the doctor–cancer patient relationship
4. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
5. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
6. Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
7. Impact d’un réseau de centre de référence pour le diagnostic et la prise en charge des patients atteints de sarcomes en France depuis 2010
8. VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
9. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
10. Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
11. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
12. 62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE
13. 54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1
14. 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study
15. 89P IMmunotherapy response associated clinical and biological PREdictive factors in advanced SARComas: A retrospective multicenter study
16. 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
17. Novel trial designs for patients with gastrointestinal stromal tumor
18. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
19. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
20. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
21. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer
22. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
23. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
24. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology
25. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
26. Surgery in reference centers improves survival of sarcoma patients: a nationwide study
27. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
28. Stratégie diagnostique devant une tumeur graisseuse des tissus mous de l’adulte
29. Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
30. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
31. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database
32. Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways
33. Improved survival using specialized multidisciplinary board in sarcoma patients
34. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
35. 190P EORTC-SPECTA Arcagen project: Results of the prospective rare thoracic tumors cohort
36. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
37. Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group
38. 157P PCM4EU academy: An educational program for precision oncology
39. 66P Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates?
40. 64P Tertiary lymphoid structure and efficacy of doxorubicin in patients with soft tissue sarcoma: The Centre Léon Bérard experience
41. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
42. Why will there never be a randomized trial for NTRK-rearranged tumors?
43. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
44. 6MO Pan-cancer characterization of receptor tyrosine kinases alterations to sort targetable drivers from passengers
45. Prostate cancer screening: contrasting trends
46. 1512P Pain in patients with desmoid fibromatosis (DF)
47. 1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS)
48. 1491MO New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis
49. 1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network
50. 1527TiP CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.